What is the Market Size of Biologics | Insights, Trends & Growth Analysis 2026

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA10717

Publication Date: Nov 2025

What is the size of Biologics Market?

According to 6Wresearch internal database and industry insights, the Global Biologics Market was valued at USD 435 Billion in 2025 and is expected to reach USD 805 Billion by 2032, growing at a compound annual growth rate of 9.10% during the forecast period (2026-2032).

The main drivers of this growth are the rapid development of advanced therapies and targeted biologic treatments, increasing incidence of chronic and complex diseases and the shift towards precision medicine encouraging uptake of biologics.

For detailed forecasts, data tables, and competitive benchmarking,
Explore the full Global Biologics Market.

View Main Report Schedule Analyst Call

Growth Factors for Biologics Industry

Expanding pipeline of monoclonal antibodies and cell-gene therapies tailored for unmet therapeutic needs.
Advancements in manufacturing technologies and modular bioprocessing facilities enhancing production scalability.
Increasing collaboration between biotech firms and contract manufacturing organisations to accelerate time to market.
Rising demand for personalised and targeted treatments replacing conventional therapies in key disease areas.
Greater regulatory support and incentive schemes for orphan biologics and novel biologic modalities.

Biologics Market Trends

The Biologics Market is witnessing trends including a growing acceptance of bispecific antibodies, antibody-drug conjugates and gene-editing therapies reshaping treatment paradigms in oncology and rare diseases. In addition, increasing biosimilar biologics, continues to promote affordability and stimulate market growth. Manufacturing technologies, including continuous bioprocessing and single-use bioreactors are gaining favor among manufacturers seeking flexibility and cost-efficient manufacturing alternatives for producing biologics.

Emerging Developments in the Biologics Market

The Biologics Market is witnessing developments like the growth of contract development and manufacturing organisations (CDMOs) offering end-to-end biologic services, enabling smaller biotechs to access large-scale capacity. Also expansion of manufacturing hubs in regions with cost advantages and regulatory harmonisation is enabling wider geographic reach of biologic therapies. Consolidation through strategic acquisitions is also accelerating portfolio expansion and manufacturing footprint among major biologics players.